1. Lubiniecki, A.S. 1988. Safety of recombinant biologics: Issues and emerging answers, p. 3: 3–12. In: Animal Cell Biotechnology, Spier, R.E. and Griffiths, J.B. (Eds.). Academic Press, London, UK.
2. Builder, S., van Reis, R., Paoni, N., Ogez, J. 1989. Process development and regulatory approval of tissue-type plasminogen activator, In: Advances in Animal Cell Biology and Technology for Bioprocesses. Spier, R.E., Griffiths, J.B., Stephenne, J., Crooy, P.J. (Eds.). Butterworths, Stoneham, MA. 452–464.
3. Division of Blood and Blood Products, U. S. Food and Drug Administration. 1984. Points to consider in the characterization of cell lines used to produce biologicals.
4. Office of Biologicals Research and Review, U. S. Food and Drug Administration. 1985. Points to consider in the production and testing of new drugs and biologicals by recombinant DNA technology.